Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease?

Currently infection with the human immunodeficiency virus-1 (HIV-1) is in most instances a chronic disease that can be controlled by effective antiretroviral therapy (ART). However, chronic use of ART has been associated with a number of toxicities; including significant reductions in bone mineral d...

Full description

Saved in:
Bibliographic Details
Main Authors: Eoin J. Cotter, Patrick W. Mallon, Peter P. Doran
Format: Article
Language:English
Published: Wiley 2009-01-01
Series:PPAR Research
Online Access:http://dx.doi.org/10.1155/2009/421376
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832568045673906176
author Eoin J. Cotter
Patrick W. Mallon
Peter P. Doran
author_facet Eoin J. Cotter
Patrick W. Mallon
Peter P. Doran
author_sort Eoin J. Cotter
collection DOAJ
description Currently infection with the human immunodeficiency virus-1 (HIV-1) is in most instances a chronic disease that can be controlled by effective antiretroviral therapy (ART). However, chronic use of ART has been associated with a number of toxicities; including significant reductions in bone mineral density (BMD) and disorders of the fat metabolism. The peroxisome proliferator-activated receptor gamma (PPAR𝛾) transcription factor is vital for the development and maintenance of mature and developing adipocytes. Alterations in PPAR𝛾 expression have been implicated as a factor in the mechanism of HIV-1-associated lipodystrophy. Both reduced BMD and lipodystrophy have been well described as complications of HIV-1 infection and treatment, and a question remains as to their interdependence. Interestingly, both adipocytes and osteoblasts are derived from a common precursor cell type; the mesenchymal stem cell. The possibility that dysregulation of PPAR𝛾 (and the subsequent effect on both osteoblastogenesis and adipogenesis) is a contributory factor in the lipid- and bone-abnormalities observed in HIV-1 infection and treatment has also been investigated. This review deals with the hypothesis that dysregulation of PPAR𝛾 may underpin the bone abnormalities associated with HIV-1 infection, and treats the current knowledge and prospective developments, in our understanding of PPAR𝛾 involvement in HIV-1-associated bone disease.
format Article
id doaj-art-f1473203346c4310b905172e39bce2dc
institution Kabale University
issn 1687-4757
1687-4765
language English
publishDate 2009-01-01
publisher Wiley
record_format Article
series PPAR Research
spelling doaj-art-f1473203346c4310b905172e39bce2dc2025-02-03T01:00:00ZengWileyPPAR Research1687-47571687-47652009-01-01200910.1155/2009/421376421376Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease?Eoin J. Cotter0Patrick W. Mallon1Peter P. Doran2Clinical Research Center, University College Dublin, Belfield, 4 Dublin, IrelandSchool of Medicine & Medical Science, University College Dublin, Belfield, 4 Dublin, IrelandClinical Research Center, University College Dublin, Belfield, 4 Dublin, IrelandCurrently infection with the human immunodeficiency virus-1 (HIV-1) is in most instances a chronic disease that can be controlled by effective antiretroviral therapy (ART). However, chronic use of ART has been associated with a number of toxicities; including significant reductions in bone mineral density (BMD) and disorders of the fat metabolism. The peroxisome proliferator-activated receptor gamma (PPAR𝛾) transcription factor is vital for the development and maintenance of mature and developing adipocytes. Alterations in PPAR𝛾 expression have been implicated as a factor in the mechanism of HIV-1-associated lipodystrophy. Both reduced BMD and lipodystrophy have been well described as complications of HIV-1 infection and treatment, and a question remains as to their interdependence. Interestingly, both adipocytes and osteoblasts are derived from a common precursor cell type; the mesenchymal stem cell. The possibility that dysregulation of PPAR𝛾 (and the subsequent effect on both osteoblastogenesis and adipogenesis) is a contributory factor in the lipid- and bone-abnormalities observed in HIV-1 infection and treatment has also been investigated. This review deals with the hypothesis that dysregulation of PPAR𝛾 may underpin the bone abnormalities associated with HIV-1 infection, and treats the current knowledge and prospective developments, in our understanding of PPAR𝛾 involvement in HIV-1-associated bone disease.http://dx.doi.org/10.1155/2009/421376
spellingShingle Eoin J. Cotter
Patrick W. Mallon
Peter P. Doran
Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease?
PPAR Research
title Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease?
title_full Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease?
title_fullStr Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease?
title_full_unstemmed Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease?
title_short Is PPAR𝛾 a Prospective Player in HIV-1-Associated Bone Disease?
title_sort is ppar𝛾 a prospective player in hiv 1 associated bone disease
url http://dx.doi.org/10.1155/2009/421376
work_keys_str_mv AT eoinjcotter ispparγaprospectiveplayerinhiv1associatedbonedisease
AT patrickwmallon ispparγaprospectiveplayerinhiv1associatedbonedisease
AT peterpdoran ispparγaprospectiveplayerinhiv1associatedbonedisease